MedPath

Sevoflurane and Hyperperfusion Syndrome

Not Applicable
Conditions
Hyperperfusion Syndrome
Moyamoya Disease
Interventions
Registration Number
NCT02510586
Lead Sponsor
Seoul National University Hospital
Brief Summary

The aim of the present study is to evaluate the effect of sevoflurane postconditioning on the incidence of postoperative hyperperfusion syndrome following revascularization surgery in moyamoya patients.

Detailed Description

Postoperative hyperperfusion syndrome is a common complication in moyamoya disease patients receiving revascularization surgery. Previously its incidence has been reported to be 17\~50%, but little remains regarding frequency of reperfusion injury after revascularization surgery in patients with moyamoya disease. Volatile anesthetics such as sevoflurane has been introduced clinically to reduce reperfusion injury and preconditioning with sevoflurane induced ischemic tolerance like as ischemic preconditioning. However, there was no report on the neuroprotective effect of sevoflurane postconditioning on ischemic/reperfusion injury in human brain. Therefore, We evaluated the neuroprotective effect of sevoflurane postconditioning on the incidence of postoperative hyperperfusion syndrome after revascularization surgery in moyamoya disease patients.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
152
Inclusion Criteria
  • Adult patients receiving cerebral revascularization surgery due to moyamoya disease
Exclusion Criteria
  • Patients who do not agree to the study
  • Patients with uncontrolled diabetes or hypertension
  • Patients using cyclooxygenase2 inhibitor or with previously using cyclooxygenase2 inhibitor
  • Patients with acute renal failure
  • Patients with previous intervention related with moyamoya disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Sevo_postconditioningSevofluranePatients receiving sevoflurane 1.0 minimum alveolar concentration (MAC) for 30 minutes after revascularization competed.
Primary Outcome Measures
NameTimeMethod
The incidence of postoperative cerebral hyperperfusion syndromepostoperative day 15

Cerebral hyperperfusion syndrome was defined if all the following four criteria were met: i) new development of postoperative focal neurological deficits, ii) a delayed neurological deficits which were not shown in the immediate postoperative period; iii) postoperative reversible neurological deficits which were completely resolved within 15 days after operation; iii) neither definite haematomas nor definite acute infarction on a brain CT scan, on diffusion magnetic resonance imaging, or both.

Secondary Outcome Measures
NameTimeMethod
The incidence of a new onset postoperative cerebral ischemiaparticipants will be followed for the duration of hospital stay, an expected average of 3 weeks.

cerebral ischemia is diagnosed by clinical symptoms and radiologic imaging (CT or MRI).

The incidence of a new onset postoperative brain hematomaparticipants will be followed for the duration of hospital stay, an expected average of 3 weeks.

postoperative brain hematoma is diagnosed by clinical symptoms and radiologic imaging (CT or MRI).

The incidence of unrecovered neurological deficitparticipants will be followed for the duration of hospital stay, an expected average of 3 weeks.

the incidence of postoperative neurological symptoms which persisted or not fully recovered until the patient's discharge.

© Copyright 2025. All Rights Reserved by MedPath